- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PET mammography reduces unnecessary biopsies
Positron-emission mammography may reduce unnecessary breast biopsies, according to data from an NIH-sponsored multisite study. Devices were provided by Naviscan.
Positron-emission mammography may reduce unnecessary breast biopsies, according to data from an NIH-sponsored multisite study. Devices were provided by Naviscan. PEM demonstrated a 6% improvement in specificity compared with breast MR, according to the research. PEM also led to 31 fewer unnecessary biopsies and a 26% higher positive predicative value compared with breast MR.
“The results of this study mean not only do physicians have an additional, powerful tool to help treat breast cancer, but that PEM is a better alternative for the 16% of women who cannot tolerate MR due to claustrophobia, metallic implants, body habitus, or gadolinium reaction,” said Dr. Wendie Berg, principal investigator for the trial and breast imaging specialist at Johns Hopkins Health Care and Surgery Center at Green Spring Station in Lutherville, MD.
The trial examined women from six locations who had newly diagnosed breast cancer. Officials for Naviscan said they have submitted the manuscript to Radiology and anticipate a response by the end of April.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
